MA31941B1 - Bis-pyridylpyridones en tant qu'antagonistes du récepteur 1 de l'hormone de concentration de la mélanine - Google Patents

Bis-pyridylpyridones en tant qu'antagonistes du récepteur 1 de l'hormone de concentration de la mélanine

Info

Publication number
MA31941B1
MA31941B1 MA32956A MA32956A MA31941B1 MA 31941 B1 MA31941 B1 MA 31941B1 MA 32956 A MA32956 A MA 32956A MA 32956 A MA32956 A MA 32956A MA 31941 B1 MA31941 B1 MA 31941B1
Authority
MA
Morocco
Prior art keywords
pyridylpyridones
antagonists
hormone receptor
bis
melanin concentration
Prior art date
Application number
MA32956A
Other languages
English (en)
Inventor
Scott Allen
Iii William C Blackwell
Eric Boros
Jon L Collins
Don Hertzog
Xi Liang
John Ray
Steven Michael Reister
Vicente Samano
Ron Sherrill
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA31941B1 publication Critical patent/MA31941B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'INVENTION CONCERNE DE NOUVELLES BIS-PYRIDYLPYRIDONES QUI SONT DES ANTAGONISTES DU RÉCEPTEUR 1 DE L'HORMONE DE CONCENTRATION DE LA MÉLANINE (MCHR1), DES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, LEURS PROCÉDÉS DE PRÉPARATION ET LEUR UTILISATION EN THÉRAPIE ET POUR LE TRAITEMENT DE L'OBÉSITÉ ET/OU DU DIABÈTE.
MA32956A 2007-12-10 2010-06-25 Bis-pyridylpyridones en tant qu'antagonistes du récepteur 1 de l'hormone de concentration de la mélanine MA31941B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1252507P 2007-12-10 2007-12-10

Publications (1)

Publication Number Publication Date
MA31941B1 true MA31941B1 (fr) 2010-12-01

Family

ID=40469812

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32956A MA31941B1 (fr) 2007-12-10 2010-06-25 Bis-pyridylpyridones en tant qu'antagonistes du récepteur 1 de l'hormone de concentration de la mélanine

Country Status (15)

Country Link
US (1) US20110118261A1 (fr)
EP (1) EP2231646A1 (fr)
JP (1) JP2011506462A (fr)
KR (1) KR20100117059A (fr)
CN (1) CN102015684A (fr)
AU (1) AU2008335187B2 (fr)
CA (1) CA2708741A1 (fr)
CO (1) CO6280470A2 (fr)
CR (1) CR11562A (fr)
EA (1) EA201070725A1 (fr)
IL (1) IL206237A0 (fr)
MA (1) MA31941B1 (fr)
MX (1) MX2010006388A (fr)
WO (1) WO2009076387A1 (fr)
ZA (1) ZA201004010B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2437598A4 (fr) * 2009-06-03 2012-10-31 Glaxosmithkline Llc Bis-pyridylpyridones en tant qu'antagonistes du récepteur de l'hormone de mélano-concentration
JP2012528871A (ja) * 2009-06-03 2012-11-15 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー メラニン凝集ホルモン受容体１アンタゴニストとしてのビス−ピリジルピリドン類
EP2807163B1 (fr) 2012-01-26 2017-03-22 H. Lundbeck A/S Inhibiteurs de pde9 comprenant un squelette imidazotriazinone
ES2750640T3 (es) * 2012-08-16 2020-03-26 Scripps Research Inst Ligandos opioides kappa novedosos
CN103044394A (zh) * 2012-12-20 2013-04-17 北京理工大学 一种苯基氨基嘧啶衍生物及其制备方法和用途
DE102015011861B4 (de) 2015-09-10 2018-03-01 Rudolf Schindler Neue cyclische Carboxamide als NMDA NR2B Rezeptor Inhibitoren
DK3596069T3 (da) * 2017-03-17 2022-08-01 Scripps Research Inst Kappa-opioid-receptor-antagonister og produkter og fremgangsmåder relateret dertil
CN110719907B (zh) 2017-06-01 2024-04-05 住友化学株式会社 杂环化合物及含有其的组合物
WO2020048831A1 (fr) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft Composés 5-aryl-3,9-diazaspiro[5.5]undécan-2-one
WO2020048828A1 (fr) 2018-09-03 2020-03-12 Bayer Pharma Aktiengesellschaft Composés du 5-hétéroaryl-3,9-diazaspiro[5.5]undécane
WO2020048830A1 (fr) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft Composés 5-aryl-3,9-diazaspiro[5.5]undécan-2-one
CN109851542A (zh) * 2019-01-28 2019-06-07 爱斯特（成都）生物制药股份有限公司 一种(s)-n-甲基-n-(吡咯烷-3-基)乙酰胺二盐酸盐及其合成方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732456B2 (en) * 2004-03-05 2010-06-08 Banyu Pharmaceutical Co., Ltd. Pyridone derivative

Also Published As

Publication number Publication date
EA201070725A1 (ru) 2011-02-28
CA2708741A1 (fr) 2009-06-18
CN102015684A (zh) 2011-04-13
EP2231646A1 (fr) 2010-09-29
CR11562A (es) 2010-09-23
AU2008335187B2 (en) 2012-03-29
IL206237A0 (en) 2010-12-30
ZA201004010B (en) 2011-03-30
WO2009076387A1 (fr) 2009-06-18
MX2010006388A (es) 2010-06-25
JP2011506462A (ja) 2011-03-03
US20110118261A1 (en) 2011-05-19
KR20100117059A (ko) 2010-11-02
AU2008335187A1 (en) 2009-06-18
CO6280470A2 (es) 2011-05-20

Similar Documents

Publication Publication Date Title
MA35208B1 (fr) Protéines de liaison à bcma (cd269/tnfrsf17)
EP2101757A4 (fr) Composé pour le traitement ou la prévention de maladies en relation avec la prostate et compositions pharmaceutiques de système d'administration par le colon contenant ce composé
MA30462B1 (fr) Composes de pyridylamide antagonistes des canaux calciques de type t
FR16C0021I2 (fr) Azetidines en tant qu'inhibiteurs de mek et leur utilisation pour le traitement des maladies proliferatives
EA201070725A1 (ru) Бис-пиридилпиридоны как антагонисты рецептора 1 меланинконцентрирующего гормона
UA112434C2 (uk) Антигензв'язувальний білок, який специфічно зв'язується з всма
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
MA33815B1 (fr) Antagonistes, de type spiro-oxindole, de l'oncoprotéine mdm2
MA31963B1 (fr) Composes antagonistes du recepteur du glucagon, compositions contenant de tels composes et procedes d'utilisation
MA41932B1 (fr) Méthodes de traitement ou de prévention de migraines
MD20070267A (en) Gastroresistant pharmaceutical formulation containing rifaximin
EP1993560A4 (fr) Antagonistes de recepteur cannabinoide/agonistes inverses utiles dans le traitement de l'obesite
EP1848431A4 (fr) Formulations liquides pour le traitement de maladies ou affections
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
UA101309C2 (ru) Антагонисты активина-actrii и их применение для повышения уровня эритроцитов
FR15C0009I2 (fr) Compositions de gel phospholipide destinees a l'administration medicamenteuse et des methodes de traitement utilisant celles-ci
MA32132B1 (fr) Utilisation de ranolazine pour traiter la douleur
MA31920B1 (fr) 4-(4-cyano-2-thioaryle)-dihydropyrimidinone et son utilisation
SG148169A1 (en) Combination drug therapy to treat obesity
MA30041B1 (fr) Immunoglobulines
MA37946A1 (fr) Traitement de la polyarthrite rhumatoïde
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
MA30413B1 (fr) Nouvelles compositions pharmaceutiques faiblement dosees contenant du nimesulide, leur preparation et utilisation
MA38190A2 (fr) Inhibiteurs d'autotaxine